Nuvalent: NVL-655 and Zidesamtinib are Convincing in pre-Treated Patients: Nuvalent (NUVL) Gets Additional Analyst Support.
Reading Time: 2 minutes
Nuvalent (NUVL) is an approximately $5.6 billion clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. Its first lead product candidate, NVL-520, is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel, ROS1-selective inhibitor designed to address the clinical challenges of emerging treatment resistance, central nervous system (CNS)-related side effects and brain metastases that may limit the use of currently available ROS1 tyrosine kinase inhibitors...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
